You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Donanemab
since
auto-detected in 1 stories
25 days ago
Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are not currently available on NHS.
page 1 of 1